AML2

If I have to stop playing in the middle of the game, do I have to start all over the next time?Click the "Take a Break" button to logoff. When you next login to AML Tour 2, you will automatically be returned to where you left off. Do I have to answer all the questions?To earn the credits, you will need to submit answers for all the questions. Is there a time limit?No, you may take as long as you like to complete the AML Tour 2. You may Take a Break and resume playing as many times as you like. If I want to get a better score, can I play again?Yes. E-mail problems@cyberounds.com notifying us that you wish to play again. Please include your full name, username and e-mail address. We will then e-mail you when you are enabled to play again. Please note: Any CME credits and the score you earned the first time will be deleted from our records permanently. If you received CME credit the first time, please print out your certificate before asking to play again.

FAQ

Similar to the Tour de France, AML Tour 2 has 20 stages plus a final post-test stage. Each stage consists of a set of questions on a particular subject. You must answer each question in the stage correctly to move forward in the game to the next stage. Before each stage, you will be asked if you would like to answer the named question set as a specialist or as a generalist. Playing as a specialist, you will have the chance to achieve a higher score but the penalty for incorrect answers is also higher. For most questions, the points you receive reflect how many submissions you needed to select the correct answer. There are 99 questions in AML Tour 2. If you play every stage as a specialist, the maximum score possible is 1485.

Release Date: December 20, 2017; Termination Date: December 19, 2018 Provider: Albert Einstein College of Medicine This CME activity is supported by independent educational grants from Astex Pharmaceuticals, Celgene, Daiichi Sankyo and Jazz Pharmaceuticals. DisclosuresThe "Faculty Disclosure Policy" of Albert Einstein College of Medicine requires that faculty participating in a CME activity disclose to the audience any relationship with a pharmaceutical, product or device company which might pose a potential, apparent or real conflict of interest with regard to their contribution to the activity. Any discussions of unlabeled or investigational use of any commercial product or device not yet approved in the United States must be disclosed. Albert Einstein College of Medicine, CCME staff, and InterMDnet staff have no relevant conflicts of interest with commercial interests related directly or indirectly to this educational activity. Einstein Peer ReviewerAmit K. Verma, M.D. Professor of Medicine (Oncology) Albert Einstein College of Medicine Einstein CME ReviewerVictor B. Hatcher, Ph.D, Associate Dean, Albert Einstein College of Medicine and Montefiore Medical Center, Bronx, NY, presents no relevant conflict-of-interest. Amit K. Verma, M.D., Professor of Medicine (Oncology), Albert Einstein College of Medicine, Bronx, NY, presents no relevant conflict-of-interest. Harry Levy, M.D., M.P.H., (interMDnet) Cyberounds® Executive Editor, presents no relevant conflict-of-interest. Within the past 12 months, Dr. Marcucci has been a consultant to Novartis, and been on the Speakers Bureau for Astellas, Novartis and Pfizer; Dr. Percival has received research support from Trillium Therapeutics; Dr. Ravandi-Kashani has received grant/research support from Amgen, BMS, Macrogenix, Seattle Genetics, Sunesis and Xencor; and consulted for Amgen and Sunesis; Dr. Raza has been on the Speakers Bureau of Novartis; and Dr. Seiter has received grant/research support from Astellas, Celator, Celgene, Daiichi-Sankyo, Forma Therapeutics, Incyte, Novartis, Onconova and Seattle Genetics, and been on the Speakers Bureau for Alexion, Amgen, Astellas, Celgene, Genoptix, Incyte, Novartis and Seattle Genetics. Overall Purpose and GoalsThe AML Tour 2 CME program focuses on the current standard therapy for AML, including special cases such as treatment of the elderly or medically less fit and those with APL, before identifying areas where new strategies and drugs are needed and examining emerging treatments for AML. Importantly, the National Comprehensive Cancer Network (NCCN) guidelines for AML highlight that participation in a clinical trial, if available, should be the first treatment choice for all patients. Target AudienceThe AML Tour 2 CME activity is certified for hematology/oncology, pediatric hematology, primary care (internal medicine, family practice and women’s health), geriatrics and for all health professionals interested in the management of AML. Educational Objectives Upon completion of this activity, you should be able to:Explain standard treatments for newly diagnosed AML for adults of all ages, including induction chemotherapy and allogeneic hematopoietic cell transplantation (HCT);Demonstrate areas in which new treatments are needed;Interpret the importance of targeted therapies, such as small molecule inhibitors or antibodies, as an adjunct to standard AML treatments to be used in their patient care.Accreditation Statement This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Albert Einstein College of Medicine and interMDnet Corporation. Albert Einstein College of Medicine is accredited by the ACCME to provide continuing medical education for physicians. Credit DesignationAlbert Einstein College of Medicine designates this educational activity for a maximum of 6.0 AMA PRA Category 1 Credits™. Physicians should claim only credit commensurate with the extent of their participation in the activity. Method of Instruction and EvaluationFormat: This activity may include conferences, graphics, sound, video, and other elements incorporated in multimedia and interactive computer based training. An evaluation form is provided at the end of AML Tour 2. You must complete the evaluation form to receive credit for the game. For AML Tour 2, credit will only be given if the CME activity is viewed in its entirety and after the evaluation form is submitted. DisclaimerThe opinions expressed herein are those of the authors and do not necessarily represent the views of the Albert Einstein College of Medicine, Genzyme Oncology or interMDnet. Please review complete prescribing information of specific drugs or combination of drugs, including indications, contraindications, warnings and adverse effects before administering pharmacologic therapy to patients. This activity is not intended to define an exclusive course of patient management; the participant should use his/her clinical judgment, knowledge, experience and diagnostic skills in applying or adopting for professional use any of the information provided herein. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients' conditions and possible contraindications or dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities. Links to other sites may be provided as additional sources of information. Once you elect to link to a new site you are subject to the terms and conditions of use, including copyright and licensing restriction, of that site. Obtaining AMA PRA Category 1 Credits™Participants who have completed the AML Tour 2 CME activity, post-test and evaluation may download a summary of their credits by clicking on the “CME” tab and then the “My Certificates” button on the Cyberounds® navbar. For credit information, please contact Einstein-Montefiore CCME: cme@montefiore.org phone: (718) 920-6674 For technical issues, please contact: levy@cyberounds.com FeesThe AML Tour 2 CME is part of the Cyberounds® Online CME program. It is a complimentary CME program. But you do first need to register for Cyberounds® if you are not already a member. All registered members of Cyberounds® can earn 6.0 AMA PRA Category 1 Credits™.

Race Rules

RETURN TO GAME

CME INFORMATION

Similar to the Tour de France, AML Tour 2 has 20 stages plus a final post-test stage. Each stage consists of sets of questions on a particular subject. You must answer each question in the stage correctly to move forward in the game to the next stage. Before each stage, you will be asked if you would like to answer the question set as a specialist or as a generalist. Playing as a specialist, you will have the chance to achieve a higher score but the penalty for incorrect answers is also higher. For most questions, the points you receive reflect how many submissions you needed to select the correct answer. There are 99 questions in AML Tour 2. If you play every stage as a specialist, the maximum score possible is 1485.

SCORING

Stage 11

Specialist level gives you more points for correct answers but a bigger penalty for incorrect answers.

dfgdfgfgdfgfg

How would you like to play this level?

Generalist

Specialist

Guido Marcucci, M.D., EndFragmentProfessor and Chair, Department of Hematologic Malignancies Translational ScienceDirector, Gehr Family Center for Leukemia ResearchCity of Hope Comprehensive Cancer Center, Duarte, CA

+ FULL BIO

Mary-Beth Percival, M.D., M.S.Assistant Professor of Medicine, University of Washington Assistant Member, the Fred Hutchinson Cancer Research Center, Seattle, WA

Farhad Ravandi-Kashani, M.D.Janiece and Stephen A. Lasher Professor of Medicine Chief, Section of Developmental Therapeutics University of Texas M.D. Anderson Cancer Center, Houston, TX

CONTINUE

Authors

Guido Marcucci, M.D., EndFragmentProfessor and Chair, Department of Hematologic Malignancies Translational Science Director, Gehr Family Center for Leukemia Research City of Hope Comprehensive Cancer Center Duarte, CA

+ FULL BIO

Farhad Ravandi-Kashani, M.D.Janiece and Stephen A. Lasher Professor of Medicine Chief, Section of Developmental Therapeutics University of Texas M.D. Anderson Cancer Center Houston, TX

Mary-Beth Percival, M.D., M.S.Assistant Professor of Medicine, University of Washington Assistant Member, the Fred Hutchinson Cancer Research Center Seattle, WA

+ FULL BIO

RETURN TO GAME

At any time during play on the AML Tour 2, you can click on Take A Break. Click here to return to Cyberounds®. There is no time limit to re-enter AML Tour 2. You can do so as many times as convenient and whenever you want. Each time you resume the AML Tour 2, you will automatically be returned to where you left off. If you complete the AML Tour 2, you will be able to earn, after submitting the post-test and the post-event evaluation, a total of six (6.0) AMA PRA Category I Credits™. No partial credit will be awarded.

Continue

Karen Seiter, M.D.Professor of Medicine, New York Medical College Director of Leukemia Service, Westchester Medical Center Valhalla, NY

Authors

Read Full Bio

Azra Raza, M.D.Chan Soon-Shiong Professor of Medicine Director, MDS Center Columbia University Medical Center New York, NY

Azra Raza, M.D. Chan Soon-Shiong Professor of Medicine Director, MDS Center Columbia University Medical Center New York, NY

Karen Seiter, M.D. Professor of Medicine, New York Medical College Director of Leukemia Service, Westchester Medical Center Valhalla, NY

Karen Seiter, M.D.Professor of Medicine, New York Medical College Director of Leukemia Service, Westchester Medical Center Valhalla, NY

+ FULL BIO

Azra Raza, M.D.Chan Soon-Shiong Professor of Medicine Director, MDS Center Columbia University Medical Center New York, NY

Upon completion of this activity, clinicians should be able to: Explain standard treatments for newly diagnosed AML for adults of all ages, including induction chemotherapy and allogeneic hematopoietic cell transplantation (HCT);Demonstrate areas in which new treatments are needed; Interpret the importance of targeted therapies, such as small molecule inhibitors or antibodies, as an adjunct to standard AML treatments to be used in their patient care.

Credit Designation:

Accreditation Statement:

Read the educational activity, complete the post-test, answer at least 70% of the post-test questions correctly and complete the activity evaluation. Certificates will be immediately available online for downloading and printing.

Albert Einstein College of Medicine designates this enduring activity for a maximum of 6.0 AMA PRA Category 1 Credits™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

Learning Objectives:

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Albert Einstein College of Medicine and interMDnet Corporation. Albert Einstein College of Medicine is accredited by the ACCME to provide continuing medical education for physicians.

To Obtain Credit, You Must:

The presentation references unlabeled/unapproved uses of the following drugs: ABT-199, entinostat, gilteritinib, GSK 79552, guadecitabine, midostaurin, OTX-015, pevonedistat, quizartinib, selinexor, sorafenib and volasertib.EndFragment

Congratulations, you have successfully completed AML Tour 2 !

Now, all you need to do is fill out the very brief, we promise, program evaluation questionnaire. Thereafter, you will be able to either download or print your CME certificate.

Congratulations, you have successfully completed AML Tour 2!

Release Date: December 20, 2017 Termination Date: December 19, 2018 Estimated time to complete this activity: 6 hours

Emerging Therapies for Acute Myeloid Leukemia

BROUGHT TO YOU BY

START

This CME activity is supported by independent educational grants from Astex Pharmaceuticals, Celgene, Daiichi Sankyo & Jazz Pharmaceuticals.

PROVIDED BY

This CME activity is supported by independent educational grants from Astex Pharmaceuticals, Celgene, Daiichi Sankyo & Jazz Pharmaceuticals.

SPECIALIST

GENERALIST

Before each stage, you will be asked if you would like to answer the particular question set as a or as a . Playing as a specialist, you will have the chance to achieve a higher score but the penalty for incorrect answers is also higher.

STAGE

Please login using your Cyberounds© Username and Password If you forgotten your password you can recover it here. If you don’t have a Cyberounds© account, click here.